文献速递物质与行为成瘾会诊联络精神医学

COVID-19与可卡因或阿片类使用障碍患者心内膜炎风险的关联

Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US.
PubMed 文献 · Mol Psychiatry · 2022-12-13

结果显示,COVID-19与OUD患者新诊断心内膜炎风险升高相关(HR: 2.23, 95% CI: 1.92-2.60),与CocaineUD患者也相关(HR: 2.24, 95% CI: 1.79-2.80)。研究提示需对感染COVID-19的阿片类或可卡因使用障碍患者进行心内膜炎筛查并链接至感染病和成瘾治疗。

要点

  • COVID-19与OUD患者新诊断心内膜炎风险升高相关(HR: 2.23, 95% CI: 1.92-2.60)。
  • COVID-19与CocaineUD患者新诊断心内膜炎风险升高相关(HR: 2.24, 95% CI: 1.79-2.80)。
  • 心内膜炎后180天住院风险:COVID-19组67.5% vs 匹配无COVID-19组58.7%(HR: 1.21, 95% CI: 1.07-1.35)。

核心结论

  • COVID-19与阿片类或可卡因使用障碍患者新诊断心内膜炎风险显著升高相关。
  • 研究提示需对感染COVID-19的阿片类或可卡因使用障碍患者进行心内膜炎筛查并链接至感染病和成瘾治疗。

研究设计与样本

  • 纳入736,502例阿片类使用障碍(OUD)患者和379,623例可卡因使用障碍(CocaineUD)患者;甲基苯丙胺使用障碍因未编码无法分析。

主要发现

  • OUD或CocaineUD患者中心内膜炎发病率从2011年至2022年显著上升,2021-2022年加速。
  • COVID-19与OUD患者新诊断心内膜炎风险升高相关(HR: 2.23, 95% CI: 1.92-2.60)。
  • COVID-19与CocaineUD患者新诊断心内膜炎风险升高相关(HR: 2.24, 95% CI: 1.79-2.80)。
  • 临床诊断的COVID-19比实验室确诊但无临床诊断的COVID-19与更高心内膜炎风险相关。
  • 心内膜炎后180天住院风险在COVID-19组为67.5%,匹配无COVID-19组为58.7%(HR: 1.21, 95% CI: 1.07-1.35)。

关键数值与推荐

  • OUD患者中COVID-19与新诊断心内膜炎关联的HR为2.23(95% CI: 1.92-2.60)。
  • CocaineUD患者中COVID-19与新诊断心内膜炎关联的HR为2.24(95% CI: 1.79-2.80)。
  • 心内膜炎后180天住院风险:COVID-19组67.5% vs 匹配无COVID-19组58.7%,HR 1.21(95% CI: 1.07-1.35)。
  • 心内膜炎后180天死亡风险:COVID-19组9.2% vs 匹配无COVID-19组8.0%,HR 1.16(95% CI: 0.83-1.61)。

临床怎么用

  • 对感染COVID-19的阿片类或可卡因使用障碍患者应考虑心内膜炎筛查。
  • 筛查阳性者应链接至感染病和成瘾治疗。

局限性

  • 甲基苯丙胺使用障碍因未编码无法分析。
  • 研究为回顾性队列设计,基于电子健康记录数据库。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The incidence of endocarditis in the US is increasing, driven in part by the rise in intravenous drug use, mostly opioids and stimulant drugs (cocaine and methamphetamine). Recent reports have documented that individuals with COVID-19 are at increased risk for cardiovascular diseases. However, it is unknown whether COVID-19 is associated with increased risk for endocarditis in patients with opioid or stimulant use disorders. This is a retrospective cohort study based on a nationwide database of electronic health records (EHRs) of 109 million patients in the US, including 736,502 patients with a diagnosis of opioid use disorder (OUD) and 379,623 patients with a diagnosis of cocaine use disorder (CocaineUD). Since Metamphetamine use disorder is not coded we could not analyze it. We show that the incidence rate of endocarditis among patients with OUD or CocaineUD significantly increased from 2011 to 2022 with acceleration during 2021-2022. COVID-19 was associated with increased risk of new diagnosis of endocarditis among patients with OUD (HR: 2.23, 95% CI: 1.92-2.60) and with CocaineUD (HR: 2.24, 95% CI: 1.79-2.80). Clinically diagnosed COVID-19 was associated with higher risk of endocarditis than lab-test confirmed COVID-19 without clinical diagnosis. Hospitalization within 2 weeks following COVID-19 infection was associated with increased risk of new diagnosis of endocarditis. The risk for endocarditis did not differ between patients with and without EHR-recorded vaccination. There were significant racial and ethnic differences in the risk for COVID-19 associated endocarditis, lower in blacks than in whites and lower in Hispanics than in non-Hispanics. Among patients with OUD or CocaineUD, the 180-day hospitalization risk following endocarditis was 67.5% in patients with COVID-19, compared to 58.7% in matched patients without COVID-19 (HR: 1.21, 95% CI: 1.07-1.35). The 180-day mortality risk following the new diagnosis of endocarditis was 9.2% in patients with COVID-19, compared to 8.0% in matched patients without COVID-19 (HR: 1.16, 95% CI: 0.83-1.61). This study shows that COVID-19 is associated with significantly increased risk for endocarditis in patients with opioid or cocaine use disorders. These results highlight the need for endocarditis screening and for linkage to infectious disease and addiction treatment in patients with opioid or cocaine use disorders who contracted COVID-19. Future studies are needed to understand how COVID-19 damages the heart and the vascular endothelium among people who misuse opioids or cocaine (presumably also methamphetamines).

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wang L, Volkow ND, Berger NA, et al. Association of COVID-19 with endocarditis in patients with cocaine or opioid use disorders in the US. Mol Psychiatry. 2022. PMID: 36510003. doi:10.1038/s41380-022-01903-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。